---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003978"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:13:27.431444+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Karyopharm reports preliminary FY2023 total revenue ~$146M, XPOVIO net product revenue ~$112M, meeting guidance

## Summary
- Full year 2023 total revenue ~$145.9M; U.S. XPOVIO net product revenue ~$112.0M; Q4 total revenue ~$33.6M.
- Cash and investments ~$192M as of Dec 31, 2023, enabling cash runway into late 2025.
- Key 2023 achievements include NCCN guideline upgrade for XVd, patent extension to Jul 2033, and ~20% workforce reduction.
- Near-term catalysts: Phase 3 readouts in 2H 2024 for multiple myeloma, enrollment completion in EC-042 for endometrial cancer, and updated myelofibrosis data.

## SEC filing metadata
- accession: 0001193125-24-003978
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312524003978/0001193125-24-003978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312524003978/d86824d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003978
- JSON: https://secwatch.observer/filing/0001193125-24-003978.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003978.txt

## Key facts
- Earnings Releases
  Karyopharm Therapeutics Inc. reported fourth quarter and full year 2023 results: revenue approximately $146 million.
  - Period: fourth quarter and full year 2023
  - Revenue: approximately $146 million
  - Result: preliminary results
  source text: Endometrial Cancer and Myelofibrosis – – Preliminary Unaudited Full Year 2023 Total Revenue and U.S. XPOVIO ® (selinexor) Net Product Revenue Expected to be Approximately $146 Million and $112 Million, Respectively, Meeting Company’s Guidance – – Potential for Selinexor to be a Novel Maintenance Treatment for Patients with TP53 Wild-Type Endometrial Cancer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312524003978/0001193125-24-003978-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.